Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | GHSR | Q92847 | 1/20 | 0.51 |
| ▸ | CCKAR | P32238 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 1/20 | 0.51 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 3/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31593292 | 0.96 | GHSR (0.57) | ACEOPRD1GHSRCCKARCCKBR | |
| SCHEMBL31593361 | 0.94 | ACE (0.59) | ACEGHSRECE1LTA4H | |
| SCHEMBL31593302 | 0.91 | NPBWR1 (0.54) | OPRD1GHSRCCKARCCKBR | |
| SCHEMBL30503004 | 0.90 | LTA4H (0.60) | ACEOPRD1OPRM1GHSRCCKAR | |
| SCHEMBL31593260 | 0.89 | NPBWR1 (0.57) | GHSR | |
| SCHEMBL30358212 | 0.89 | ACE (0.54) | ACEOPRD1OPRM1TACR1 | |
| SCHEMBL31593374 | 0.88 | GHSR (0.64) | ACEGHSR | |
| SCHEMBL30051742 | 0.87 | ACE (0.68) | ACEECE1LTA4H | |
| SCHEMBL31593284 | 0.87 | NPBWR1 (0.58) | GHSR | |
| SCHEMBL30291168 | 0.86 | ERAP2 (0.54) | ACEOPRD1CCKARCCKBRECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | ACE 2907/4885OPRD1 3704/4885OPRM1 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.